Latham & Watkins Advises NiKang Therapeutics In Completion of US$200 Million Series C Financing

A San Diego corporate team advised the clinical stage biotech company in the transaction that will advance highly differentiated small molecules addressing difficult-to-drug targets.

May 27, 2021

NiKang Therapeutics Inc. (NiKang), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, announced the completion of an oversubscribed US$200 million series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors, and Logos Capital.

Latham & Watkins LLP represented NiKang in the transaction with a San Diego-based corporate team led by San Diego partner Cheston Larson and San Diego associate Evan Youngstrom.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.